December 2023
1. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
   Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
   Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
   

   >> Share

   
   June 2023
2. PALANDRI F, Breccia M, Mazzoni C, Auteri G, et al
   Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
   Cancer. 2023;129:1704-1713.
   

   >> Share

   
   March 2023
3. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
   Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies".
   Cancer. 2023 Mar 14. doi: 10.1002/cncr.34736.
   

   >> Share

   
   
4. MANCUSO A, Butera G, Rossi M, Maringhini A, et al
   Hepatocellular carcinoma in thalassemia and other hemoglobinopathies.
   Cancer. 2023 Mar 14. doi: 10.1002/cncr.34735.
   

   >> Share

   
   January 2023
5. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
   Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021.
   Cancer. 2023;129:107-117.
   

   >> Share

   
   December 2022
6. GAO Y, Liu Y, Wang Y, Zhang Q, et al
   Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
   Cancer. 2022 Dec 21. doi: 10.1002/cncr.34544.
   

   >> Share

   
   October 2022
7. KUYKENDALL AT, Mo Q, Sallman DA, Ali NA, et al
   Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
   Cancer. 2022;128:3495-3501.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share